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Abstract
Background: Tumor suppressor genes (TSGs) encode the guardian molecules to control cell growth. The genomic
alteration of TSGs may cause tumorigenesis and promote cancer progression. So far, investigators have mainly
studied the functional effects of somatic single nucleotide variants in TSGs. Copy number variation (CNV) is another
important form of genetic variation, and is often involved in cancer biology and drug treatment, but studies of CNV
in TSGs are less represented in literature. In addition, there is a lack of a combinatory analysis of gene expression
and CNV in this important gene set. Such a study may provide more insights into the relationship between gene
dosage and tumorigenesis. To meet this demand, we performed a systematic analysis of CNVs and gene expression
in TSGs to provide a systematic view of CNV and gene expression change in TSGs in pan-cancer.
Results: We identified 1170 TSGs with copy number gain or loss in 5846 tumor samples. Among them, 207 TSGs
tended to have copy number loss (CNL), from which fifteen CNL hotspot regions were identified. The functional
enrichment analysis revealed that the 207 TSGs were enriched in cancer-related pathways such as P53 signaling
pathway and the P53 interactome. We further performed integrative analyses of CNV with gene expression using
the data from the matched tumor samples. We found 81 TSGs with concordant CNL events and decreased gene
expression in the tumor samples we examined. Remarkably, seven TSGs displayed concordant CNL and gene down-
regulation in at least 50 tumor samples: MTAP (212 samples), PTEN (139), MCPH1 (85), FBXO25 (67), SMAD4 (64), TRIM35
(57), and RB1 (54). Specifically to MTAP, this concordance was found in 14 cancer types, an observation that is not much
reported in literature yet. Further network-based analysis revealed that these TSGs with concordant CNL and gene
down-regulation were highly connected.
Conclusions: This study provides a draft landscape of CNV in pan-cancer. Our findings of systematic concordance
between CNL and down-regulation of gene expression may help better understand the TSG biology in tumorigenesis
and cancer progression.
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Background
Cancer is characterized by unconstrained cell proliferation.
In the normal cell, there is precise control of cell division
such as cell cycle check points [1]. In cellular system, tumor
suppressor genes (TSGs) are important guardian genes that
protect a normal cell from one step on the path to uncon-
trolled growth [2, 3]. In cancer cells, TSGs may lose their
normal functions because of mutations occur at its critical
sites. For single nucleotide or small insertions/deletions
(indels), these mutations often lead to truncation of tran-
scripts or proteins, including nonsense mutations, splicing
site mutations, or frameshift mutations. Similar effects can
be caused by larger scale mutations, such as copy number
variations (CNVs), gene fusions, or structural variants (SVs)
[4, 5]. The mutated TSGs often coordinate with oncogenes
for cancer progression [4, 6, 7]. Therefore, the identification
and understanding of TSGs have profound influence to
develop the diagnosis biomarkers and effective drugs for
cancer therapies.
CNVs are the variable number of DNA fragments in
the human genome. Their lengths typically range from a
kilo base pairs to a mega base pairs [8]. CNVs are
divided into two major groups: copy number loss (CNL)
and copy number gain (CNG). CNL denotes the
decreased gene (or sequence fragment) copies in the
genome while CNG denotes the gain of additional gene
copies in the human genome. With the development of
high throughput technologies such as Comparative
genomic hybridization (CGH) array and next-generation
sequencing, a very large number of CNVs, as well as other
types of mutations and genomics data (e.g., gene expres-
sion) have been unveiled, especially in cancer genomes
[9, 10]. This allows us to systematically study cancer muta-
tion signatures, heterogeneity, and other molecular
features [11]. For CNV, such deleted or duplicated DNA
fragments often have profound effects on gene expression,
which subsequently affects gene’s function [12].
Despite a number of studies have explored CNVs and
gene expression in various cancers [13], there has been no
systematic study of the features in TSGs yet. Moreover,
the results from single cancer type may not be representa-
tive in other types of cancer, or they may vary among the
subtypes of the cancer. To overcome these limitations, we
conducted a pan-cancer CNV analysis on TSGs to explore
the landscape of CNV features and cross-validate some
observations. This study may help us better elucidate the
relationship between CNV and gene expression change in
this important gene category in cancer.
Methods
The curated TSGs from thousands of literatures
To conduct a systematic CNV survey of TSGs, we down-
loaded all the 1207 curated human TSGs from TSGene
database in a plain text format with all the Entrez Gene
IDs and official symbols (version 2.0) [2]. In this version of
TSGene database, there were 1088 protein-coding and
198 non-coding TSGs. All these TSGs were manually
curated from over 9000 PubMed abstracts by us. To anno-
tate TSGs with CNVs, it requires the genomic location for
mapping. Therefore, we downloaded the corresponding
RefSeq mapping information for TSGs from RefSeq data-
base. We implemented an in-house script to extract all
the genomic location information from the completed
human genome RefSeq sequences (accession number
starting with NC). In total, 1207 TSGs were annotated
with accurate genomic locations in GRCH 38.
The pan-cancer CNV data from The Cancer Genome Atlas
(TCGA)
To explore the CNVs in pan-cancer systematically, we
downloaded all the prepared TCGA CNV data with the
GRCH 38 genomic coordinates from the Catalogue of
Somatic Mutations in Cancer (COSMIC) database (V73).
When integrating TCGA data, COSMIC introduced a few
thresholds to define the copy number loss and gain. CNG
was obtained by the following criteria: (the average genome
ploidy < =2.7 AND total DNA segment copy number > =5)
OR (average genome ploidy >2.7 AND total DNA segment
copy number > =9). Similarly, the criteria for CNL were:
(the average genome ploidy < =2.7 AND total DNA seg-
ment copy number =0) OR (average genome ploidy >2.7
AND total DNA segment copy number < (average genome
ploidy – 2.7)). In this study, we followed COSMIC criteria
and overlapped all the CNV regions with TSGs using the
GRCH 38 coordinates. By intersecting all the CNV gain
and loss information to all the 1207 TSGs with GRCH 38
coordinates, we annotated 1170 TSGs with precise gain or
loss information. For each cancer type, we calculate the
number of samples with CNL and CNG, respectively. Since
TSGs are often in loss-of-function in cancer progression,
we pulled out those TSGs with higher frequency of CNLs
than that with CNGs. Specifically, we set a cut-off of 2 to
filter out those TSGs without having at least twice of tumor
samples with CNLs as tumor samples with CNGs. This
process resulted in 207 TSGs with the evidence of an over-
all loss of CNVs. These genes were used for the following
gene expression analysis.
Gene expression analysis for TSGs with CNL
To check the CNV-correlated gene expression changes on
TSGs, we downloaded the TCGA pan-cancer gene expres-
sion data from the COSMIC database (V73). In this study,
we focused on only those gene expression changes in the
matched TCGA samples with TSG CNLs. For the gene
expression quantification, COSMIC started from FPKM
calculated using trimmed short reads generate by the
RNA-Seq platform and the RSEM quantification results
from the RNAseq V2 platform. Here, FPKM denotes
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Fragments Per Kilobase of transcript per Million mapped
reads, which is used to indicate the relative expression of a
transcript. And RSEM is one of the popular measures for
accurate transcript quantification of RNA-Seq data. The
average and the standard deviation of expression were
computed using those tumor samples that are diploid for
each corresponding gene.
The standard Z score was used to characterize whether
a TSG is over or under expressed. The Z-score with abso-
lute value 2 was used as the threshold value. The Z-score
over 2 was defined as over expression while the Z-score
less than −2 represented the decreased gene expression.
For those 81 TSGs with CNL-associated gene expres-
sion change, we further systematically examined their
somatic CNV patterns in pan-cancer of TCGA samples
using cBio portal [14].
Sub-network extraction for the TSGs with high frequency
CNLs
To explore the relevant biological mechanisms related to
TSGs with frequently observed CNLs and consistent
gene down-regulation, we extracted a PPI network to
connect 81 TSGs with the remaining human genes. To
this goal, we started from a non-redundant human inter-
actome extracted from the Pathway Commons database
[15, 16], containing 3629 proteins and 36,034 PPIs. It is
worth noting that this integrated human interactome is
based on well-curated pathway databases (HumanCyc,
Reactome, and KEGG pathway database [17]). Therefore,
those links in the interactome have biological meaning
rather than physical interactions. Based on the pathway-
based interactions, we used the similar approach imple-
mented in our previous study to extract a sub-network
related to our 81 TSGs [16, 18, 19]. In this sub-network
extraction strategy, all the 81 seed TSGs were over-
lapped to the human pathway-based interactome. Then,
a sub-network with the maximum number of the seed
TSGs was formed by connecting each TSG through the
shortest path. To characterize the function of the net-
work, we relied on the network topological properties
(degree and shortest path) calculated from the network.
In practice, we utilized NetworkAnalyzer plugin in
Cytoscape 2.8 to compute topological properties in the
TSG network [20]. The degree is defined as the number
of direct connections of each node with other nodes in
the TSG network [21, 22]. The network layout was con-
ducted based on Cytoscape 2.8 [20].
Results
Genomic regions with frequent copy number loss in TSGs
in multiple cancer types
To systematically survey the somatic CNVs in TSGs, our
pipeline started with a list of 1207 human TSGs from
the TSGene 2.0 database [2, 23] (Fig. 1). These genes
have multiple lines of evidence in literature and other
data, and have been manually curated. To provide an
unbiased global view of CNVs in major types of cancer,
we overlapped all these 1207 TSGs with the somatic
CNVs identified from TCGA, which is the largest cancer
genomics data source. This resulted in a list of non-
redundant 1170 TSGs, which are annotated with CNVs
(Additional file 1: Table S1). However, the majority
CNVs are not informative due to the lack of matched
control tissue. In this study, we only focused on those
TSGs with precise gain or loss data using the normal tis-
sue as control (see Methods). By counting the number
of samples with gain or loss of gene copies, we set a
threshold to prioritize most informative CNV events for
TSGs. Since TSGs typically play their roles by loss-of-
function, we used only those TSGs that tend to have
copy number loss. To this end, we required CNVs were
observed in at least as twice the samples with copy num-
ber loss as those with copy number gain. The process re-
sulted in a total of 207 TSGs. We named them as TSGs
with CNL in cancer, and used them for the follow up
functional enrichment and integrative analyses. The list
is provided in Additional file 2: Table S2.
We performed functional enrichment analysis of these
207 genes using Gene Ontology (GO) terms as func-
tional units. Figure 2 displays the main features of GO-
related functional features, and their clusters. Overall,
they are enriched with cell proliferation, apoptosis, cell
Fig. 1 Pipeline for the identification of concordant copy number
loss and down-regulation of tumor suppressor genes in human cancer.
This figure shows the pipeline for identifying the tumor suppressor
genes (TSGs) with concordant copy number variations (CNVs) and gene
expression. It involves four main steps. 1) Downloading TSGs from the
TSGene 2.0 database and overlapping to the TCGA pan-cancer CNV
data. 2) The resulted 1170 TSGs with CNV overlapping information were
further extracted and calculated the precise copy number gain (CNG)
and loss (CNL). 3) Based on the number of samples with CNGs and
CNLs in the pan-cancer CNV data, we collected 207 TSGs with frequent
CNLs. 4) Using the gene expression data from the matched TCGA
cancer samples, we identified 81 TSGs with consistent CNLs and
decreased gene expression in the same samples
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cycle, and growth control; all are important features of
cancer cells. The TSGs with CNL also have fundamental
roles in development such as embryonic morphogenesis
and reproduction. In addition, they involve in negative
regulation of cell metabolism and protein phosphoryl-
ation. Some TSGs may influence cell communication,
cell junction assembly, and response to the extracellular
stimulus.
Interestingly, the 207 TSGs could highly cluster into fif-
teen chromosome regions. All these regions had the cor-
rected enrichment p-values less than 0.01 (Table 1). Among
the 15 regions, eight could be further clustered into three
genomics locations: 3p21, 8p21-22, and 17p13.1-3. In 3p21,
we found four enriched cytobands with a total of 27 TSGs.
For example, the 3p21.3 cytoband is enriched with 14 TSGs
(CTDSPL, CYB561D2, LIMD1, MST1R, NPRL2, PTPN23,
RASSF1, RBM5, RBM6, RHOA, SEMA3B, SEMA3F,
TUSC2, and ZMYND10). Another six TSGs (CDCP1, LTF,
MIR1226, SETD2, SMARCC1, and TDGF1) were clustered
in 3p21.31. The remaining 7 TSGs were located close to
3p21. These 27 TSGs in 3p21 had CNLs in 129 TCGA
samples covering 20 different cancer types. Specific to the
tissue site, there were 27, 20, 15, 15, and 11 samples from
lung, central nervous systems, kidney, breast, and large in-
testine, respectively. A similar observation of the high fre-
quency of loss involving the short arm of chromosome 3
was reported as a tumor suppressor locus in a variety of
histologically different neoplasms more than twenty years
ago [24, 25]. However, our survey provides precise locations
in various cancer samples.
On chromosome 8, the 8p22 locus contained 7 neigh-
bouring TSGs (CCAR2, DLC1, LZTS1, MIR383, MTUS1,
SOX7, and ZDHHC2), while another 8 TSGs (BNIP3L,
DOK2, EXTL3, MIR320A, PIWIL2, PPP3CC, RHOBTB2,
and TNFRSF10A) clustered at 8p21. These 15 TSGs at
8p21-22 had CNL detected in 219 TCGA patients. The
cancer tissues that had most frequent CNLs in TSGs at
this locus are breast (61 samples), lung (42 samples),
large intestine (30 samples), ovary (23 samples), and
prostate (11 samples). Another CNL hot region is at
17p13.1-3, which covers 14 TSGs, including the most stud-
ied TSG TP53. This region on chromosome 17 had detect-
able CNLs in a total of 50 TCGA tumor samples.
Interestingly, the above three genomic regions with frequent
Fig. 2 Gene Ontology (GO) analysis of 207 human tumor suppressor genes (TSGs) with frequent copy number losses (CNLs). The scatterplot
shows the GO clusters for the 207 TSGs with CNLs in a two-dimensional space derived by applying multidimensional scaling to a matrix of the
GO terms' semantic similarities. Bubble color represents the frequency of the GO term in the GOA database (more general terms are toward red).
Bubble size indicates the log of corrected p-value (the smaller corrected p-value, the larger bubble)
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CNLs in TSGs harbour not only well-known protein-coding
TSGs such as TP53, but also six microRNAs (MIRLET7G,
MIR135A1, MIR195, MIR320A, MIR383, and MIR497). By
overlapping to TSGene database, we found all the six micro-
RNAs are tumor suppressor microRNAs. Collectively, our
systematic examination on CNL in TSG cluster regions pro-
vides precise information of such CNL in multiple cancers.
The results may be useful for further studying the similar or
different roles of CNL in differential cancer types as well as
cancer heterogeneity.
Correlation of CNL with gene expression decrease using
the matched tumor samples
Through incorporating the gene expression change of the
TCGA samples with the CNL on TSGs, we examined the
correlation between CNL and TSG gene down-regulation.
We utilized the Z-score to assess whether a TSG is up-
regulated or down-regulated in specific TCGA samples.
Here, Z-score is a transformation of the p value calculated
by the formula as below:
Z ¼ x‐μ
σ
Where μ represents the mean expression of a gene
across multiple TCGA samples; σ represents the stand-
ard deviation of the expression scores of the gene in
TCGA samples. Specifically, we used the Z-score thresh-
old value −2 to identify down-regulated TSGs in specific
TCGA samples.
After examining the same TCGA tumor samples for
both expression and CNV loss, we found 81 TSGs that
had concordant decreased gene expression and loss of
gene copy numbers in tumor samples (Additional file 3:
Table S3). The functional enrichment analyses revealed
that the 81 TSGs are mainly associated with cancer-
related pathways such as cell cycle (adjusted P-value =
1.15E-6) (Additional file 4: Table S4). Interestingly, they
are also related to a number of cancer-related phenotypes
such as hamartomatous polyposis (adjusted P-value =
1.05E-6) and intussusception (adjusted P-value = 3.98E-6).
The CNV mutational patterns across multiple cancers are
plotted in Fig. 2. In terms of their CNVs, these 81 TSGs
are highly mutated. For example, in TCGA esophageal car-
cinoma cohort, there were 142 cases (77.2 %) that had at
least one gene with copy number change (Additional file 5:
Table S5). More than 50 % of the esophageal carcinoma pa-
tients had at least one deletion event in one of the 81
TSGs. The similar prevalence of copy number alteration
(>60 % cases, including both CNLs and CNGs) was found
in other 11 cancer datasets from 9 cancer types: metastatic
prostate cancer, malignant peripheral nerve sheath tumor,
sarcoma, ovarian serous cystadenocarcinoma, lymphoid
neoplasm diffuse large B-cell lymphoma, bladder urothelial
carcinoma, glioblastoma multiforme, uterine carcinosar-
coma, and stomach adenocarcinoma. However, specific to
CNLs, only the glioblastoma multiforme (GBM) cohort
had over 60 % patients with CNLs (Fig. 3, the blue bar rep-
resent the CNLs in different cancer types). Although the
other cancer cohorts also possess CNLs in the majority of
the affected patients, a small portion of patients had CNGs
rather than CNLs. This may imply the importance of the
81 TSGs in cancer progression of GBM via the massive
copy number losses.
To further explore the potential CNL-induced gene
expression change, we specifically checked four TSGs
with the most frequently observed CNLs; all these genes
were observed in more than 50 tumor samples. As
shown in Fig. 4, TSG MTAP had CNL in more than
40 % cases in TCGA GBM cohort. The TSG MCPH1
was deleted in more than 14 % patients in a prostate
cancer dataset. PTEN showed similar frequent CNV loss
in prostate cancer samples. The gene loss of SMAD4
Table 1 The 15 genomics regions associated with 207 tumor
suppressor genes (TSGs) with frequent copy number losses (CNLs)
Cytoband p-value q-value # TSGs TSG list
3p21.3 5.98E-19 3.48E-16 14 CTDSPL, CYB561D2, LIMD1,
MST1R, NPRL2, PTPN23, RASSF1,
RBM5, RBM6, RHOA, SEMA3B,
SEMA3F, TUSC2, ZMYND10
8p22 4.48E-09 9.78E-07 7 CCAR2, DLC1, LZTS1, MIR383,
MTUS1, SOX7, ZDHHC2
11p15.5 5.05E-09 9.78E-07 10 CDKN1C, H19, MIR210, MIR483,
NUP98, RNH1, SIRT3, TRIM3,
TSPAN32, TSSC4
17p13.1 5.30E-08 7.71E-06 9 ALOX15B, BCL6B, GABARAP,
MIR195, MIR497, TNK1, TP53,
XAF1, ZBTB4
19p13.3 2.52E-06 2.93E-04 10 AMH, DAPK3, DIRAS1, FZR1,
GADD45B, PLK5, SIRT6, STK11,
TCF3, TNFSF9
8p21.3 3.45E-06 3.34E-04 5 DOK2, MIR320A, PIWIL2, PPP3CC,
RHOBTB2
3p21.31 3.63E-05 3.01E-03 6 CDCP1, LTF, MIR1226, SETD2,
SMARCC1, TDGF1
3p21.1 1.49E-04 1.02E-02 4 ACY1, CACNA2D3, MIR135A1,
MIRLET7G
6q26 1.58E-04 1.02E-02 3 MAP3K4, IGF2R, PACRG
10q24-q25 2.09E-04 1.16E-02 2 CHUK, MXI1
8p21 2.19E-04 1.16E-02 3 BNIP3L, EXTL3, TNFRSF10A
17p13.3 2.40E-04 1.16E-02 5 ALOX15, MNT, MYBBP1A,
PAFAH1B1, VPS53
22q13.31 2.62E-04 1.17E-02 4 FBLN1, MIRLET7B, MIRLET7A3,
PPARA
9p21 7.46E-04 3.10E-02 3 CDKN2A, CDKN2B, MTAP
3p21 1.08E-03 4.19E-02 3 GNAT1, MST1, PBRM1
q-values were calculated by Benjamini-Hochberg multiple testing correction of
the raw p-values, which were calculated by the hypergeometric test
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Fig. 3 A pan-cancer global view of copy number variation (CNV) features based on 81 tumor suppressor genes (TSGs) with decreased gene expression
potentially induced by copy number losses (CNLs)
Fig. 4 A pan-cancer view of copy number of variation (CNV) distribution in four tumor suppressor genes: MTAP, MCPH1, PTEN, and SMAD4. The
CNV mutational landscape for (a) MTAP, (b) MCPH1, (c) PTEN, and (d) SMAD4
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was prominent in the pancreatic cancer. Furthermore,
we found consistent, low gene expression of these four
genes in the tumor samples with CNL (Fig. 5). The re-
sults suggested that CNL might induce gene expression
decrease as a common mechanism in cancer.
A connected biological map of TSGs with concordant CNL
and decreased gene expression
To further investigate the common functional regulation
and enhance our understanding of the cellular events of
these 81 TSGs with decreased expression and CNL, we
conducted a pathway-based protein-protein interaction
(PPI) analysis using the pathway annotation data from
Pathway Commons database [15]. These reliable interac-
tions are based on evidence from known biological path-
ways such as the KEGG and Reactome pathway databases.
Therefore, this pathway-based interactome is useful for
the pathway reconstruction because such pathways may
avoid high-level noises, sparseness, and highly skewed
degree distribution, which are often observed in physical
interaction-based PPI networks. By applying the Klein-Ravi
algorithm for module searching [18], we first mapped the
81 TSGs to the human pathway interactome. Then, a sub-
network was extracted, allowing to connect as many as the
81 TSGs as possible. The reconstructed TSG network con-
tains 54 nodes and 56 links (Fig. 6a). Among the 54 nodes,
35 are from the 81 TSGs. The remaining 19 are the linker
genes to bridge those TSGs so that a fully connected map
could be built. The degrees of the nodes in this recon-
structed map potentially follow a power law distribution
P(k) ~ k-b, where P(k) is the probability that a node has con-
nections with other k nodes and b is an exponent with an
estimated value of 1.4 (Fig. 6b). Moreover, most of the
genes in the network can be connected by three to five
steps on average, as measure by the shortest path (Fig. 6c).
These two topological features (degree and shortest path)
indicated that most TSGs in this map were closely con-
nected with high modularity. Considering the tight
Fig. 5 The correlation of copy number variation (CNV) and gene expression in four tumor suppressor genes: MCPH1, MTAP, PTEN, and SMAD4.
a MTAP using TCGA glioblastoma data, (b) MCPH1 using TCGA breast cancer data, (c) PTEN using TCGA lung squamous carcinoma (LUSC), and
(d) SMAD4 using TCGA colorectal cancer data
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connection of the map, the nodes with multiple connec-
tions are likely to play critical and concordant roles to me-
diate biological regulation such as signalling transduction in
cellular system. In the network, there are 7 nodes with four
or more connections: TP53 (12 connections), SMAD4 (6),
TGFBR2 (6), MAP3K1 (5), HSP90AA1 (5), ATM (4), and
SP1 (4). It is interestingly that TP53 is the node with
most connection in the network. SMAD4 is also in
the centre of the map with six connections. In sum-
mary, our reconstructed map for the 81 TSGs with
potential CNL-driven gene down-regulation contains
some interesting features such as the TSGs with po-
tential CNL-induced dysregulation.
Discussion
This study revealed some important somatic mutational
features of TSGs in multiple cancer types, particularly
with respect to the CNVs and their effects on gene ex-
pression. Since the loss-of-function is the typical mech-
anism that TSGs involve in cancer initiation and
progression, a large-scale change of gene copy number
may induce gene expression alteration. In this scenario,
a critical regulation change is that CNL in a TSG leads
to the over-expression of its guardian genes. Although
previous studies have explored the balance of germline
CNVs and gene expression, there still lack of direct links
of somatic CNVs on gene expression dosage compensa-
tion. In this study, we only focused on the concordant
patterns between CNL and gene down-regulation
because TSGs often play functions in a manner of loss-
of-function. Our results only provided the insight of cor-
relation between gene dosage and somatic CNV; more
systematic examination of the expression quantitative
trait locus may provide more depth on the relationship
between CNV and gene expression.
This study was mainly based on the TCGA genomic
data. The cohort size of some cancer types is relatively
small (e.g., ~100 samples). A small sample size may filter
out many low-frequency CNVs. In addition, TCGA mainly
relies on the CGH array between normal and tumor tis-
sues to characterize CNVs, which may lose signals outside
of pre-designed probes. These undetected CNVs may also
contribute to TSGs functionality on cancer progression.
Another limitation in this study is that we only incorpor-
ate the protein-coding gene expression, not including
non-coding gene expression. The further integration of
large-scale CNV data and gene expression of noncoding
RNA (microRNA and long non-coding RNA) may provide
new insight into the roles of the non-coding TSGs.
In this study, we made an effort to construct a bio-
logical map for the genes with consistent CNL and gene
down-regulation in cancer. Although the majority of
genes in the reconstructed map are linked with each
other, the size of the network is relatively small. There-
fore, it has limited power to explore the overall network
functions based on the topological features. For example,
we found the degree of the network might follow the
power-law distribution. This feature is different from the
Fig. 6 Reconstructed interaction map for the 81 tumor suppressor genes (TSGs) with decreased gene expression potentially induced by copy
number losses (CNLs). a The network includes 35 genes (in yellow) from the 81 TSGs with decreased expression potentially induced by CNLs and
19 linker genes (in blue) that connect these 35 TSGs. The node size reflects the number of connection. A bigger size means more connections
associated with the gene. b The degree distribution of the nodes (genes) in the network (a). c The distribution of the shortest path length
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whole human PPI network, in which the majority nodes
(genes) are sparsely connected with exponent b as 2.9
[26]. It is not sufficient to impose the scale-free proper-
ties on this constructed small network due to the small
size. For the same reason, it is not good for us to define
the hub nodes based on the high connectivity. Neverthe-
less, the nodes with multiple connections in our network
should provide some clues for the common CNL events
related to gene down-regulation. The further experimen-
tal validation may provide more insight into the poten-
tial molecular mechanisms for those CNL events that
were detected in multiple cancers.
Conclusions
In conclusion, our systematic exploration of copy num-
ber variations on human TSGs revealed that the copy
number loss of TSGs cluster in a few genomics regions.
These TSGs with frequent copy number loss often have
profound roles in cancer-related pathways. The loss of
copy number in a number of TSGs may contribute to
the gene expression change involving tumorigenesis.
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